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Coronary artery bypass grafting (CABG), one of the most common cardiac surgical procedures, is characterized by a burst of
oxidative stress. 8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), produced following DNA repairing, is used as an indicator of
oxidative DNA damage in humans. The eﬀect of CABG on oxidative-induced DNA damage, evaluated through the
measurement of urinary 8-oxodG by a developed and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS)
method in 52 coronary artery disease (CAD) patients, was assessed before (T0), ﬁve days (T1), and six months (T2) after CABG
procedure. These results were compared with those obtained in 40 subjects with cardiovascular risk factors and without overt
cardiovascular disease (CTR). Baseline (T0) 8-oxodG was higher in CAD than in CTR (p = 0 035). A signiﬁcant burst was
detected at T1 (p = 0 019), while at T2, 8-oxodG levels were signiﬁcantly lower than those measured at T0 (p < 0 0001) and
comparable to those found in CTR (p = 0 73). A similar trend was observed for urinary 8-iso-prostaglandin F2α (8-isoPGF2α),
a reliable marker of oxidative stress. In the whole population baseline, 8-oxodG signiﬁcantly correlated with 8-isoPGF2α
levels (r = 0 323, p = 0 002). These data argue for CABG procedure in CAD patients as inducing a short-term increase in
oxidative DNA damage, as revealed by 8-oxodG concentrations, and a long-term return of such metabolite toward
physiological levels.
1. Introduction
Although coronary artery bypass grafting (CABG) is one of
the most common cardiac surgical procedures, patients’
morbidity and mortality, due to its adverse postoperative
complications, are exceedingly high [1]. To investigate the
mechanism underlying such adverse events, studies have
assessed the biochemical eﬀect of oxidative stress during this
procedure [2, 3]. Reactive oxygen species (ROS), which are
thought to be, at least in part, responsible for such adverse
events, show a burst during CABG [4]. However, whilst the
lipid peroxidation [5, 6] and the antioxidant defenses [7, 8]
have been already evaluated, only limited information is
available on oxidative DNA damage [9].
In human cells, the balance between DNA damage/repair
is a ﬁnely regulated physiological process, resulting in
approximately 104 oxidized DNA bases eliminated for cell
for day in healthy subjects [10]. The oxidative modiﬁcation
of DNA by ROS can generate a variety of possible DNA
lesions. Among nucleobases, guanine has the lowest redox
potential, thus, being the most susceptible to oxidation [11].
Indeed, its stable urinary end-product, 8-oxo-7,8-dihydro-
2′-deoxyguanosine (8-oxodG), is one of the most widely
recognized biomarkers of oxidative DNA damage [12, 13].
This metabolite, mirroring a ROS-damaged guanine muta-
genic eﬀect (due to its tendency to preferentially pair with
adenine over cytosine during DNA replication, leading to
G-to-T point mutation [14]), has been measured in several
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pathological conditions [15–18]. In particular, studies in
patients with atherosclerotic cardiovascular disease highlight
that 8-oxodG is signiﬁcantly associated with both coronary
artery disease (CAD) and other types of atherosclerotic
diseases (stroke, peripheral artery disease, and carotid
atherosclerosis) [19].
Little is known concerning 8-oxodG and cardiac surgery.
Here, we report 8-oxodG levels in CAD patients undergoing
CABG procedure, before and at diﬀerent times after surgery,
and in control subjects with cardiovascular risk factors and
without overt cardiovascular disease (CTR).
As stated by the European Standards Committee on
Urinary (DNA) Lesion Analysis (ESCULA), a fully recog-
nized method to determine 8-oxodG is not deﬁned so
far [20]. Therefore, to measure this analyte, a simple and
reliable liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method has been developed and validated
and will be presented here. Finally, we report data on the
association between urinary levels of 8-oxodG and 8-iso-
prostaglandin F2α (8-isoPGF2α), a well-recognized index of
lipid peroxidation [21].
2. Materials and Methods
2.1. Chemicals and Reagents. 8-oxodG was purchased from
Sigma-Aldrich (St. Louis, MO, USA); 15N5-8-oxodG was
from Cambridge Isotope Laboratories, Inc. (Andover, MA,
USA), and 8-iso-PGF2α and 8-iso-PGF2α-d4 were from
Cayman Chemicals Co. (Ann Arbor, MI, USA). Amicon®
Ultra centrifugal ﬁlters (Ultracel®-30K) were purchased
from Merck Millipore Ltd. (Cork, Ireland), and Sep-Pak®
C18 solid-phase extraction (SPE) cartridges (3 cc, 500mg)
were purchased from Waters (Milford, MA, USA). Puriﬁed
water was obtained from Milli-Q® Integral system (Merck
Millipore Ltd., Cork, Ireland). All other chromatography-
grade chemicals were obtained from Sigma-Aldrich.
2.2. Study Population. Over a six-month period (January
2011–June 2011), 52 consecutive CAD patients undergo-
ing CABG surgery on extracorporeal circulation (ECC)
were enrolled in the present study at Centro Cardiologico
Monzino (CCM). Inclusion criteria were as follows: the
need of an elective, isolated surgical procedure; age between
18 and 80 years; heart ejection f raction > 30%; normal sinus
rhythm; no history of atrial ﬁbrillation; coronary angiog-
raphy carried out at least ﬁve days before the surgical
procedure. Exclusion criteria were as follows: renal or liver
disease; intake of antioxidant products (e.g., vitamins). Forty
subjects with cardiovascular risk factors (e.g., diabetes,
obesity, hypertension, smoking habit, and dyslipidemia with-
out overt cardiovascular disease, on the basis of laboratory
tests and clinical examination) acted as CTR group.
Informed consent to participate to this observational
study, which was approved by CCM Institutional Review
Board, was obtained by all subjects. The study protocol con-
forms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by the Institution’s
Human Research Committee.
2.3. Study Protocol and Sample Collection and Preparation.
CTR’s urinary samples were collected at the scheduled visit.
To assess the eﬀect of CABG intervention on oxidative-
induced DNA damage in CAD patients, we collected urine
samples before (T0), ﬁve days (T1), and six months after
(T2) CABG procedure. Both in CTR and patients, all urine
specimens for 8-oxodG measurement were collected early
in the morning, aliquoted in tubes, and stored at −80°C until
analysis. Frozen urine were thawed at room temperature,
heated at 37°C for 10 minutes to redissolve possible analyte
precipitates [22, 23], and then centrifuged at 1,700×g for
10 minutes. Subsequently, 200μL aliquots were diluted
with 200μL of 15N5-8-oxodG internal standard solution
(ﬁnal concentration 5ng/mL) and ﬁltered through a 30,000
NMWL (nominal molecular weight limit) centrifugal ﬁlters
at 10,000×g for 30 minutes. The ﬁltrate was injected into
the LC–MS/MS system.
For 8-iso-PGF2α, the processing of the collected urine
was previously published [24].
2.4. 8-oxodG Measurement. An LC–MS/MS method was
set up and validated to measure urinary 8-oxodG levels.
The analytical instrument was an Accela HPLC System
(Thermo Fisher Scientiﬁc, San Jose, CA, USA) coupled to a
triple-quadrupole mass spectrometer TSQ Quantum Access
(Thermo Fisher Scientiﬁc) outﬁtted with electrospray ioniza-
tion (ESI) source operating in positive mode. The chromato-
graphic separation was performed using a pentaﬂuorophenyl
Kinetex F5 100Å analytical column (100× 2.1mm, Phenom-
enex, Torrance, CA, USA) packed with 2.6μm core-shell par-
ticles, maintained at 30°C. The mobile phase was set at a ﬂow
rate of 0.25mL/min using ammonium acetate 10mmol/L
(solvent A) and ammonium acetate 10mmol/L in acetoni-
trile/water 50 : 50 v/v (solvent B). Samples (10μL) were eluted
with a gradient of mobile phase (Supplementary Table 1
available online at https://doi.org/10.1155/2017/9715898)
during a total run time of 14 minutes. The selected reaction
monitoring (SRM) was performed by monitoring the transi-
tionsm/z 284.0➔m/z 168.1 (8-oxodG) andm/z 289.0➔m/z
173.0 (15N5-8-oxodG). The operating conditions for MS
analysis were the following: spray voltage, 2200V; capillary
temperature, 280°C; sheath gas, 25UA; auxiliary gas, 10UA.
The Xcalibur® software, version 2.0 (Thermo Fisher Scien-
tiﬁc), was used for system control, data acquisition, and
processing. The method validation was based on U.S. Food
and Drug Administration [25] and Matuszewski et al. [26]
guidelines, including the evaluation of imprecision, linearity
range, lower limit of quantiﬁcation (LLOQ), limit of detec-
tion (LOD), relative matrix eﬀect (ME), extraction recovery
(RE), process eﬃciency (PE), and sample stability. Validation
process details are reported in Supplementary Material.
2.5. 8-iso-PGF2α Measurement. 8-Iso-PGF2α determination
was performed by modifying a previously described LC-
MS/MS method [24]. Brieﬂy, the chromatographic sepa-
ration was performed using an XBridge® C18 column
(100× 2.1mm, particle size 3.5μm; Waters Milford, MA,
USA) maintained at 30°C. The mobile phase was composed
by two solvents: water with 0.1% ammonium hydroxide
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(solvent A) and methanol : acetonitrile 50 : 50 v/v with 0.1%
ammonium hydroxide (solvent B). The following gradient
was used: 0min—15% B, 14min—50% B, 16min—90% B,
22min—15% B, and 40min—15% B. SRM was per-
formed in negative mode by monitoring the transitions
m/z 353.1 ➔ m/z 192.8 (8-iso-PGF2α) and m/z 357.05 ➔
m/z 197.1 (8-iso-PGF2α-d4).
The estimated analyte values were corrected for the
urinary creatinine levels, to control the variation in urinary
output, and expressed as ng/mg of creatinine (8-oxodG) or
pg/mg of creatinine (8-iso-PGF2α) [27]. Urinary creatinine
was measured by a standard method in the clinical laboratory
of CCM using Jaﬀe’s reaction.
2.6. Statistical Analysis. Continuous variables are presented
as mean± standard deviation (SD) and were compared using
the t-test for independent samples. Categorical variables
were compared using chi-square test or Fisher’s exact test,
as appropriate.
As 8-oxodG and 8-iso-PGF2α values showed a nonnor-
mal distribution, they were log transformed and their time
courses were evaluated by covariance analysis for repeated
measures. Data were adjusted with multivariable models
for age and sex and expressed as geometric mean (GM)
with 95% conﬁdence intervals (95% CI). The Pearson cor-
relation was used to detect correlations between 8-oxodG
and 8-iso-PGF2α at T0. A p value <0.05 was considered
statistically signiﬁcant.
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, North Carolina).
3. Results
3.1. Population. Demographic, clinical, and laboratory fea-
tures of the two study groups are reported in Table 1. CAD
patients were more hypercholesterolemic and hypertensive
than CTR subjects; however, total cholesterol, LDL, and
HDL were lower in the patient group as a result of the
ongoing pharmacological treatments. There was no correla-
tion between 8-oxodG levels and clinical parameters of the
studied population.
3.2. 8-oxodG Method Validation. A representative chromato-
gram of 8-oxodG and of its internal standard 15N5-8-oxodG
in urine pool sample, resulting from the chromato-
graphic conditions and the selected transitions, is shown in
Figure 1. The peaks eluted at 3.33min, in a region of the
chromatogram without any interfering background peaks.
The 10-point calibrator concentrations, plotted against
the ratio of analyte/internal standard areas for ﬁve con-
secutive assays, showed linear and reproducible curves
with the following nonzero forced linear regression equa-
tions: y = 0 1609 ± 0 006 x− 0 0143 ± 0 035 r2 = 0 999 .
Over the entire concentration range of the curve, the mean-
observed percentage deviation of back-calculated concentra-
tions was between −0.7% and +3.8% with an imprecision
coeﬃcient of variation CV < 15%. However, as the human
urine 8-oxodG concentration seldom exceeds 20ng/mL,
samples quantiﬁcation was performed using a calibration
curve in the range 0.25–25 ng/mL.
Intra-assay and interassay imprecisions were <10% for all
quality controls (QC) tested; the LLOQ was 0.25 ng/mL while
LOD value was 0.1 ng/mL. Detailed information are provided
in Supplementary Table 2.
Supplementary Table 3 shows the relative ME, the RE,
and the overall PE of the method. No relative matrix
eﬀect was observed at the three concentrations evaluated.
Recovery and process eﬃciency values complied with the
acceptability requirements, indicating a good reliability of
the developed method.
The analyte was highly stable in urine at diﬀerent temper-
atures of storage for at least 6 months and even throughout
three freeze-thaw cycles (Supplementary Table 4).
3.3. 8-oxodG Levels in CAD Patients Undergoing CABG
Surgery. In Figure 2 the 8-oxodG levels in CAD and CTR
are depicted. As shown, the values of 8-oxodG measured in
CAD patients before surgery (T0) (GM: 2.66 ng/mg creati-
nine, 95% CI: 2.39–2.95), were signiﬁcantly higher than those
Table 1: Overall population characteristics at baseline.
Variables
CAD
(n = 52)
CTR
(n = 40) p value
Demographic characteristics
Age, years 63.5± 9.7 58.5± 7.0 0.004
Male gender, number (%) 40 (76.9) 22 (55.0) 0.014
Clinical characteristics
Weight, kg 75.6± 13.8 78.1± 13.7 0.390
BMI, kg/m2 26± 5.2 27.5± 4.1 0.080
Active smokers, number (%) 6 (11.5) 6 (15) 0.630
Biochemical
Total cholesterol, mg/dL 190.7± 44.2 212.5± 29.0 0.004
LDL cholesterol, mg/dL 121.8± 35.6 139.5± 32.4 0.020
HDL cholesterol, mg/dL 48.0± 10.6 52.7± 12.9 0.004
Triglycerides, mg/dL 104.0± 41.6 130.3± 82.4 0.070
Fasting glycemia, mg/dL 117.7± 28.1 107.0± 31.3 0.190
Creatinine, mg/dL 149.9± 77.3 125.2± 51.8 0.070
Comorbidities
Diabetes, number (%) 7 (13.5) 1 (2.5) 0.080
Hypertension, number (%) 48 (92.3) 17 (42.5) 0.005
Hypercholesterolemia,
number (%)
29 (55.8) 9 (22.5) 0.001
Obesity, number (%) 1 (1.9) 5 (12.5) 0.070
Medications
Aspirin, number (%) 33 (63.5) 0 (0) p < 0 001
Statins, number (%) 28 (53.9) 4 (10) p < 0 001
Oral hypoglycemics,
number (%)
7 (13.5) 1 (2.5) 0.160
Antihypertensive,
number (%)
48 (92.3) 13 (32.5) p < 0 001
Characteristics of the study groups: CAD patients (n = 52) and CTR subjects
(n = 40). Values are presented as mean ± SD or in absolute numbers
(percentage of total).
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found in CTR (GM: 2.26 ng/mg creatinine, 95% CI: 2.00–
2.56) (p = 0 035). In contrast, six months after the interven-
tion (T2) (Figure 2), 8-oxodG levels of CAD patients were
entirely comparable to those of CTR (GM: 2.04 ng/mg
creatinine, 95% CI: 1.84–2.27 and 2.26 ng/mg creatinine,
95% CI: 2.00–2.56, resp.; p = 0 73).
8-oxodG values at the diﬀerent time points are shown
in Figure 3(a). There was a statistical signiﬁcant increase
of short-term oxidative DNA damage after cardiac surgery
(delta T1-T0, p = 0 019) and a signiﬁcant decrease after six
months from the intervention (delta T2-T1, p < 0 0001)
with a full recovery at T2 (delta T2–T0, p < 0 0001), up to
normal values.
No correlation between 8-oxodG levels and ECC or
clamping time (r = 0 115, p = 0 42, and r = 0 205, p = 0 1,
resp.) was observed.
3.4. 8-Iso-PGF2α Levels in CAD Patients Undergoing CABG
Surgery. Levels of 8-iso-PGF2α in CAD patients undergoing
surgery are depicted in Figure 3(b). Similar to 8-oxodG, an
increase in 8-iso-PGF2α values was observed following the
surgical procedure (delta T1-T0, p = 0 003) that returned to
basal levels six months later (delta T2-T1, p < 0 0001).
However, no signiﬁcant diﬀerence was found before and six
months after CABG procedure (delta T2–T0, p = 0 205).
At variance with 8-oxodG, no signiﬁcant diﬀerences
were found in 8-iso-PGF2α values between CTR (GM:
141.2 pg/mg creatinine 95% CI: 117.25–170.06) and CAD
patients before surgery (T0) (GM: 155.06 pg/mg creatinine
95% CI: 132.45–181.53).
3.5. Correlation between 8-iso-PGF2α and 8-oxodG Levels. As
shown in Figure 4, at baseline, a direct and positive correla-
tion was found in the whole population studied (n = 92)
between the two oxidative stress markers considered, 8-
oxodG and 8-iso-PGF2α (r = 0 323, p = 0 002).
4. Discussion
The aim of this study was to assess the eﬀect of CABG
procedure on the oxidative stress status in CAD patients.
To reach this goal, we decided to measure 8-oxodG, a marker
of oxidative DNA damage, 5 days and 6 months after CABG
surgery. For this purpose, we developed an LC-MS/MS
method to quantify urinary 8-oxodG level. Although LC-
MS/MS is the gold standard technique to measure 8-oxodG
[27–29], and various methods are currently employed (as
8-oxodG
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Figure 1: Representative chromatogram of 8-oxodG and of its internal standard 15N5-8-oxodG in urine pool sample.
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stated by ESCULA), none of them is, up to now, overall
accepted [20]. The LC-MS/MS method that we have devel-
oped and validated is simple, sensitive, and reliable and can
be proposed in routine determination of 8-oxodG levels.
Following the application of this method, we show that,
before CABG procedure, CAD patients have signiﬁcantly
higher urinary 8-oxodG levels as compared to CTR. Previ-
ously published studies in diﬀerent matrices (serum [30],
DNA extracts from leukocyte or lymphocytes [31, 32], and
urine [33, 34]) showed higher than normal 8-oxodG concen-
trations in atherosclerotic patients. Moreover, a previously
published meta-analysis [19] documented a statistically sig-
niﬁcant higher concentrations of 8-oxodG in CAD patients
than in control subjects. In keeping with this, enhanced 8-
oxodG concentrations have been reported in atherosclerotic
plaques compared to the underlying media or to nonathero-
sclerotic mammary arteries [35] and to elevated DNA strand
breaks in cells isolated from the atherosclerotic lesions [36].
8-oxodG measurement in cardiovascular disease allows to
evaluate oxidative damage from a diﬀerent point of view,
catching a picture of ROS-induced mutagenic eﬀect. Indeed,
as previously discussed, 8-oxodG reﬂects mutagenic guanine
damage that may mispair with adenine, leading to a G-to-T
point mutation during replication [14].
The return of 8-oxodG concentrations toward control
values in CAD patients six months after cardiac surgery
reveals the recovery of oxidative stress toward physiological
levels. It is conceivable that CABG procedures, probably in
association with pharmacological therapy, reduce oxidative
stress and, in turn, ischemia-related DNA damage in
CAD patients. Established atherogenic risk factors such as
hypertension, smoking habits, and diabetes mellitus have
been associated to an increased oxidative stress [37]; how-
ever, the pre- and postsurgical schedules for the treatment
of these risk factors did not change in the present setting.
The present data also provide evidence for a short-term
burst of 8-oxodG associated with CABG surgery, highlight-
ing a signiﬁcant increase of this metabolite 5 days after
procedure. A higher than normal oxidative stress has been
associated to CABG, and it is considered a risk factor for
postoperative complications such as morbidity and mor-
tality, in this very frequent cardiac intervention [1]. The
observed increase in oxidative DNA damage and oxidative
stress at T1 is likely to reﬂect the overproduction of ROS
due to surgical trauma and/or ischemia-reperfusion process.
The contact of blood with polymers of the extracorporeal
circuit may also induce neutrophil activation and, in turn,
ROS production [38]. However, we did not observe any
correlation between ECC or clamping time and 8-oxodG
levels in the present setting. Karahalil et al. assessed the
short-term eﬀects of CABG surgery on 8-oxodG serum
levels [9], but they did not observe any diﬀerence in the
levels of 8-oxodG in samples obtained before versus after
surgery. Diﬀerences in the matrices and in the collection
times employed may well explain the discrepancies between
the present data and those obtained by Karahalil et al.
Our results clearly highlight that CABG surgery causes
a burst of oxidative damage both in DNA and lipids (as
depicted by the increase of 8-oxodG and 8-isoPGF2α, resp.).
In line with other studies in this area [39–41], we have found
a direct positive baseline correlation between urinary 8-iso-
PGF2α and 8-oxodG in samples obtained from CAD patients
and CTR. However, England and coworkers showed no cor-
relation between these two markers in healthy subjects [42].
These authors measured these metabolites in white cells (as
to 8-oxodG) and in plasma (as to 8-isoPGF2α), leading to
the hypothesis that measuring both analytes in the same
matrix may probably give a more reliable assessment of the
in vivo oxidative stress status and an explanation for the
discrepancy between the two data.
In addition to similarities, these two markers of oxidative
stress also show potential diﬀerences in the oxidative stress
evaluation. The fact that, at variance with 8-oxodG, 8-iso-
PGF2α levels were entirely comparable to those obtained 6
months after surgery deserves some considerations. Being
an index of lipid peroxidation, 8-iso-PGF2α levels are likely
to be inﬂuenced by plasma cholesterol levels and by the
ongoing treatments on total and LDL cholesterol [43].
Table 1 indicates that plasma total, LDL, and HDL choles-
terol are signiﬁcantly higher in CTR than in CAD patients,
a ﬁnding consistent with an ongoing, probably long-term,
statin treatment (as also reported in Table 1) and a more
intensive lipid-lowering strategy of (pharmacological/nutri-
tional) intervention in the present CAD setting. In addition,
hypertension [44], smoking habits, [45] and diabetes [46]
(recognized cardiovascular risk factors) show a positive
correlation with 8-iso-PGF2α and their presence in the CTR
could mask the diﬀerences between the groups.
Our study has some potential limitations. The controls
employed do not entirely match the clinical characteristics
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of the 52 subjects that underwent CABG surgery. However,
consecutive patients were chosen, and the inclusion/exclu-
sion criteria employed were stringent enough to avoid major
biases. Another possible limitation is the small number of
subjects enrolled. Future investigation in the area, with larger
numbers of patients, will help to conﬁrm and extend the
clinical impact of the present ﬁndings.
5. Conclusion
The LC-MS/MS method developed and validated in our
laboratory allows monitoring the oxidative DNA damage
without interfering with patient’s postoperative progress,
being urine as one of the simplest biological matrices. The
results obtained in this study highlight a short-term oxidative
DNA damage induced by CABG procedure in CAD patients
and a complete recovery of this oxidative burst six months
after the procedure.
Overall, our results argue for normalization of oxidative
DNA damage vis-à-vis correction of ischemia-related ROS
damage in CAD patients.
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